The recent surge in investments into boutique pharmaceutical companies, particularly those focusing on novel therapies and challenging drug development programs, has fueled what some are calling "High Investor Pharma." While the possibility for blockbuster treatments and significant returns is certain, the connected risks are also considerable. Man